Konstantin Mechler1, William K Mountford2, Georg F Hoffmann3, Markus Ries3. 1. Pediatric Psychopharmacology, Department of Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. 2. Department of Clinical Research, School of Nursing, College of Health and Human Services, University of North Carolina at Wilmington, Wilmington, North Carolina, USA. 3. Pediatric Neurology and Center for Rare Disorders, Center for Pediatric and Adolescent Medicine, Heidelberg University Hospital, Heidelberg, Germany.
Abstract
PURPOSE: Experimental treatment with substrate replacement was successfully performed in single cases with molybdenum cofactor deficiency type A. The objective of this study was to quantitate the yet undefined natural history in untreated patients to ultimately benefit knowledge in experimental treatments in the future. METHODS: Systematic analysis of published cases with molybdenum cofactor deficiency. The main outcome measures were survival, initial cardinal disease features at onset, and diagnostic delay. RESULTS: The median survival for the overall population was 36 months. Initial cardinal disease features at onset were seizures (72%) as well as feeding difficulties (26%) and hypotonia (11%). In addition, developmental delay (9%), hemiplegia (2%), lens dislocation (2%), and hyperreflexia (1%) were reported. The median age at onset of the disease was the first day of life; the median age at diagnosis was 4.5 months. The median time to diagnosis (diagnostic delay) was 89 days. CONCLUSION: Molybdenum cofactor deficiency has its onset during the neonatal period and infancy. There is considerable diagnostic delay. Although seizures were the most frequent initial cardinal sign, molybdenum cofactor deficiency should be considered as a differential diagnosis in patients presenting with hypotonia, developmental delay, or feeding difficulties. The survival data will inform further natural-history and therapeutic studies.
PURPOSE: Experimental treatment with substrate replacement was successfully performed in single cases with molybdenum cofactor deficiency type A. The objective of this study was to quantitate the yet undefined natural history in untreated patients to ultimately benefit knowledge in experimental treatments in the future. METHODS: Systematic analysis of published cases with molybdenum cofactor deficiency. The main outcome measures were survival, initial cardinal disease features at onset, and diagnostic delay. RESULTS: The median survival for the overall population was 36 months. Initial cardinal disease features at onset were seizures (72%) as well as feeding difficulties (26%) and hypotonia (11%). In addition, developmental delay (9%), hemiplegia (2%), lens dislocation (2%), and hyperreflexia (1%) were reported. The median age at onset of the disease was the first day of life; the median age at diagnosis was 4.5 months. The median time to diagnosis (diagnostic delay) was 89 days. CONCLUSION: Molybdenum cofactor deficiency has its onset during the neonatal period and infancy. There is considerable diagnostic delay. Although seizures were the most frequent initial cardinal sign, molybdenum cofactor deficiency should be considered as a differential diagnosis in patients presenting with hypotonia, developmental delay, or feeding difficulties. The survival data will inform further natural-history and therapeutic studies.
Authors: A Mehta; M Beck; P Elliott; R Giugliani; A Linhart; G Sunder-Plassmann; R Schiffmann; F Barbey; M Ries; J T R Clarke Journal: Lancet Date: 2009-12-12 Impact factor: 79.321
Authors: Günter Schwarz; José Angel Santamaria-Araujo; Stefan Wolf; Heon-Jin Lee; Ibrahim M Adham; Hermann-Josef Gröne; Herbert Schwegler; Jörn Oliver Sass; Tanja Otte; Petra Hänzelmann; Ralf R Mendel; Wolfgang Engel; Jochen Reiss Journal: Hum Mol Genet Date: 2004-04-28 Impact factor: 6.150
Authors: Marrit M Hitzert; Arend F Bos; Klasien A Bergman; Alex Veldman; Guenter Schwarz; José Angel Santamaria-Araujo; Rebecca Heiner-Fokkema; Deborah A Sival; Roelineke J Lunsing; Sita Arjune; Jos G W Kosterink; Francjan J van Spronsen Journal: Pediatrics Date: 2012-09-17 Impact factor: 7.124
Authors: F Weidemann; M Niemann; S Störk; F Breunig; M Beer; C Sommer; S Herrmann; G Ertl; C Wanner Journal: J Intern Med Date: 2013-05-06 Impact factor: 8.989
Authors: Maha S Zaki; Laila Selim; Hala T El-Bassyouni; Mahmoud Y Issa; Iman Mahmoud; Samira Ismail; Mariane Girgis; Abdelrahim A Sadek; Joseph G Gleeson; Mohamed S Abdel Hamid Journal: Eur J Paediatr Neurol Date: 2016-05-30 Impact factor: 3.140
Authors: Barbara Scelsa; Serena Gasperini; Andrea Righini; Maria Iascone; Valeria G Brazzoduro; Pierangelo Veggiotti Journal: Mol Genet Genomic Med Date: 2019-03-21 Impact factor: 2.183
Authors: Stephen F Kingsmore; Nanda Ramchandar; Kiely James; Anna-Kaisa Niemi; Annette Feigenbaum; Yan Ding; Wendy Benson; Charlotte Hobbs; Shareef Nahas; Shimul Chowdhury; David Dimmock Journal: Cold Spring Harb Mol Case Stud Date: 2020-02-03